| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 113 | 2023 | 884 | 25.580 |
Why?
|
| Anaphylaxis | 82 | 2023 | 746 | 20.380 |
Why?
|
| Desensitization, Immunologic | 84 | 2023 | 483 | 17.320 |
Why?
|
| Mastocytosis | 42 | 2023 | 160 | 13.320 |
Why?
|
| Mast Cells | 67 | 2023 | 1544 | 8.000 |
Why?
|
| Mastocytosis, Systemic | 21 | 2023 | 100 | 7.140 |
Why?
|
| Tryptases | 33 | 2023 | 190 | 5.730 |
Why?
|
| Hypersensitivity | 26 | 2023 | 1102 | 4.710 |
Why?
|
| Skin Tests | 37 | 2023 | 613 | 3.340 |
Why?
|
| Immunoglobulin E | 33 | 2023 | 1463 | 2.940 |
Why?
|
| Mastocytosis, Cutaneous | 7 | 2020 | 14 | 2.570 |
Why?
|
| Insect Bites and Stings | 6 | 2023 | 67 | 2.400 |
Why?
|
| Antineoplastic Agents | 32 | 2023 | 13695 | 2.320 |
Why?
|
| Penicillins | 10 | 2023 | 380 | 2.310 |
Why?
|
| Hymenoptera | 7 | 2023 | 13 | 2.260 |
Why?
|
| Antibodies, Monoclonal | 22 | 2022 | 9274 | 2.140 |
Why?
|
| Arthropod Venoms | 5 | 2023 | 10 | 2.060 |
Why?
|
| Allergens | 14 | 2023 | 1320 | 1.950 |
Why?
|
| Taxoids | 10 | 2021 | 666 | 1.810 |
Why?
|
| Basophils | 10 | 2020 | 389 | 1.770 |
Why?
|
| Hypersensitivity, Immediate | 10 | 2022 | 337 | 1.670 |
Why?
|
| Hypersensitivity, Delayed | 6 | 2021 | 484 | 1.640 |
Why?
|
| Carboplatin | 7 | 2023 | 801 | 1.640 |
Why?
|
| Biological Factors | 3 | 2017 | 164 | 1.480 |
Why?
|
| Biological Products | 5 | 2022 | 860 | 1.440 |
Why?
|
| Receptors, IgE | 7 | 2023 | 389 | 1.420 |
Why?
|
| Basophil Degranulation Test | 4 | 2019 | 16 | 1.350 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 1071 | 1.280 |
Why?
|
| Paclitaxel | 6 | 2020 | 1708 | 1.240 |
Why?
|
| Urticaria Pigmentosa | 3 | 2019 | 17 | 1.240 |
Why?
|
| Anti-Allergic Agents | 7 | 2021 | 141 | 1.230 |
Why?
|
| Vaccination | 6 | 2022 | 3278 | 1.170 |
Why?
|
| Humans | 251 | 2024 | 744343 | 1.120 |
Why?
|
| Blister | 3 | 2019 | 86 | 1.120 |
Why?
|
| Angioedema | 3 | 2017 | 187 | 1.080 |
Why?
|
| Platinum Compounds | 2 | 2016 | 96 | 1.060 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 2 | 2024 | 54 | 1.060 |
Why?
|
| Epinephrine | 10 | 2022 | 792 | 0.930 |
Why?
|
| beta-Lactams | 4 | 2023 | 160 | 0.880 |
Why?
|
| Wasp Venoms | 3 | 2019 | 18 | 0.880 |
Why?
|
| Platinum | 2 | 2021 | 233 | 0.830 |
Why?
|
| Drug Eruptions | 4 | 2019 | 297 | 0.800 |
Why?
|
| Intraoperative Complications | 4 | 2018 | 1198 | 0.770 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 12 | 2020 | 2282 | 0.760 |
Why?
|
| Histamine Antagonists | 4 | 2020 | 93 | 0.760 |
Why?
|
| Anti-Bacterial Agents | 18 | 2023 | 7181 | 0.760 |
Why?
|
| Urticaria | 3 | 2021 | 150 | 0.740 |
Why?
|
| Leukotriene Antagonists | 2 | 2019 | 127 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-kit | 8 | 2022 | 776 | 0.720 |
Why?
|
| Neoplasms | 16 | 2022 | 21683 | 0.710 |
Why?
|
| Amoxicillin | 4 | 2023 | 170 | 0.710 |
Why?
|
| Organoplatinum Compounds | 5 | 2013 | 408 | 0.700 |
Why?
|
| Bacitracin | 1 | 2018 | 25 | 0.670 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 634 | 0.660 |
Why?
|
| Viral Vaccines | 2 | 2021 | 636 | 0.640 |
Why?
|
| Antigens | 5 | 2017 | 1466 | 0.630 |
Why?
|
| Phenotype | 11 | 2023 | 16365 | 0.630 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 570 | 0.620 |
Why?
|
| Food Hypersensitivity | 7 | 2018 | 622 | 0.610 |
Why?
|
| Ovarian Neoplasms | 7 | 2016 | 4838 | 0.600 |
Why?
|
| Actins | 2 | 2023 | 2121 | 0.600 |
Why?
|
| Allergy and Immunology | 3 | 2019 | 169 | 0.580 |
Why?
|
| Meglumine | 1 | 2017 | 149 | 0.580 |
Why?
|
| Perception | 3 | 2018 | 1198 | 0.570 |
Why?
|
| Interleukin-6 | 3 | 2020 | 3200 | 0.560 |
Why?
|
| Cystic Fibrosis | 2 | 2019 | 1177 | 0.550 |
Why?
|
| Fibrinolysis | 1 | 2017 | 322 | 0.550 |
Why?
|
| Connective Tissue Diseases | 1 | 2019 | 264 | 0.550 |
Why?
|
| Progesterone | 4 | 2022 | 776 | 0.550 |
Why?
|
| Acetates | 3 | 2019 | 311 | 0.540 |
Why?
|
| Breast Implantation | 1 | 2018 | 218 | 0.540 |
Why?
|
| Quinolones | 1 | 2019 | 367 | 0.530 |
Why?
|
| Wasps | 1 | 2015 | 13 | 0.530 |
Why?
|
| Anesthetics | 4 | 2018 | 539 | 0.510 |
Why?
|
| Iduronidase | 1 | 2014 | 31 | 0.500 |
Why?
|
| Female | 83 | 2024 | 380194 | 0.490 |
Why?
|
| Autoimmune Diseases | 4 | 2022 | 2133 | 0.490 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2014 | 50 | 0.480 |
Why?
|
| Goals | 1 | 2019 | 706 | 0.480 |
Why?
|
| Antirheumatic Agents | 2 | 2015 | 1339 | 0.470 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3133 | 0.470 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.470 |
Why?
|
| Latex Hypersensitivity | 2 | 2003 | 13 | 0.470 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2013 | 63 | 0.460 |
Why?
|
| Progestins | 4 | 2022 | 306 | 0.460 |
Why?
|
| Maytansine | 1 | 2014 | 80 | 0.460 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 665 | 0.450 |
Why?
|
| Cross Reactions | 6 | 2021 | 841 | 0.440 |
Why?
|
| Cisplatin | 3 | 2013 | 1662 | 0.440 |
Why?
|
| Penicillanic Acid | 2 | 2024 | 45 | 0.430 |
Why?
|
| Receptors, Immunologic | 6 | 2001 | 1423 | 0.430 |
Why?
|
| Adult | 53 | 2023 | 214055 | 0.420 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 654 | 0.420 |
Why?
|
| Middle Aged | 52 | 2022 | 213383 | 0.410 |
Why?
|
| Quinolines | 3 | 2019 | 732 | 0.410 |
Why?
|
| Quality of Life | 11 | 2023 | 12804 | 0.410 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2006 | 624 | 0.400 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 794 | 0.400 |
Why?
|
| Exanthema | 4 | 2024 | 501 | 0.400 |
Why?
|
| Erythema | 1 | 2012 | 257 | 0.390 |
Why?
|
| Vaccines | 2 | 2019 | 822 | 0.390 |
Why?
|
| Patient Preference | 1 | 2018 | 890 | 0.390 |
Why?
|
| Diarrhea | 4 | 2022 | 1348 | 0.390 |
Why?
|
| Cromolyn Sodium | 4 | 2019 | 87 | 0.380 |
Why?
|
| Glucocorticoids | 2 | 2020 | 2107 | 0.370 |
Why?
|
| Male | 62 | 2022 | 350118 | 0.370 |
Why?
|
| Aspirin | 6 | 2019 | 3282 | 0.360 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 1149 | 0.350 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1130 | 0.350 |
Why?
|
| Genital Neoplasms, Female | 2 | 2005 | 523 | 0.340 |
Why?
|
| Pruritus | 1 | 2012 | 361 | 0.340 |
Why?
|
| Thalidomide | 1 | 2014 | 890 | 0.330 |
Why?
|
| Anesthesia | 3 | 2011 | 1561 | 0.330 |
Why?
|
| Skin | 7 | 2019 | 4364 | 0.330 |
Why?
|
| Disease Management | 5 | 2021 | 2459 | 0.330 |
Why?
|
| Sulfides | 3 | 2019 | 165 | 0.320 |
Why?
|
| Perioperative Care | 4 | 2014 | 1002 | 0.320 |
Why?
|
| Intradermal Tests | 4 | 2018 | 44 | 0.320 |
Why?
|
| Pandemics | 4 | 2022 | 8388 | 0.320 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 15540 | 0.320 |
Why?
|
| Animals | 34 | 2023 | 168757 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.320 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 1354 | 0.310 |
Why?
|
| Cyclopropanes | 3 | 2019 | 416 | 0.310 |
Why?
|
| Cefazolin | 2 | 2007 | 96 | 0.300 |
Why?
|
| Antigens, Surface | 5 | 2001 | 1663 | 0.290 |
Why?
|
| Asthma | 5 | 2020 | 6011 | 0.290 |
Why?
|
| Mastocytoma | 1 | 2006 | 5 | 0.290 |
Why?
|
| RNA, Messenger | 3 | 2022 | 13033 | 0.280 |
Why?
|
| Famotidine | 2 | 2019 | 16 | 0.280 |
Why?
|
| Histamine | 4 | 2019 | 507 | 0.260 |
Why?
|
| Eosinophilia | 2 | 2011 | 541 | 0.260 |
Why?
|
| Contrast Media | 3 | 2018 | 5300 | 0.260 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2019 | 536 | 0.260 |
Why?
|
| Membrane Glycoproteins | 6 | 2001 | 3768 | 0.250 |
Why?
|
| Inflammation Mediators | 4 | 2012 | 1889 | 0.250 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1580 | 0.250 |
Why?
|
| Consensus | 7 | 2024 | 2959 | 0.250 |
Why?
|
| Infertility, Female | 1 | 2010 | 787 | 0.240 |
Why?
|
| Minocycline | 1 | 2005 | 163 | 0.240 |
Why?
|
| Histamine H2 Antagonists | 2 | 2019 | 165 | 0.240 |
Why?
|
| Injections, Subcutaneous | 2 | 2017 | 666 | 0.230 |
Why?
|
| Staurosporine | 2 | 2018 | 251 | 0.230 |
Why?
|
| Bone Marrow | 7 | 2020 | 2948 | 0.230 |
Why?
|
| Treatment Outcome | 18 | 2018 | 63114 | 0.230 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 2455 | 0.230 |
Why?
|
| Aged | 26 | 2021 | 163280 | 0.220 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2013 | 1632 | 0.220 |
Why?
|
| Fertilization in Vitro | 1 | 2010 | 1284 | 0.220 |
Why?
|
| Child | 18 | 2023 | 77709 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 17446 | 0.210 |
Why?
|
| Chemokines | 1 | 2006 | 970 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 1170 | 0.200 |
Why?
|
| Syndrome | 5 | 2013 | 3251 | 0.200 |
Why?
|
| Immunoglobulin G | 3 | 2021 | 4560 | 0.200 |
Why?
|
| Penicillin G | 1 | 2021 | 42 | 0.200 |
Why?
|
| Receptors, Vitronectin | 1 | 2001 | 52 | 0.200 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2023 | 431 | 0.200 |
Why?
|
| Leukotriene E4 | 2 | 2019 | 79 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 20822 | 0.190 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2002 | 93 | 0.190 |
Why?
|
| Retrospective Studies | 10 | 2024 | 77449 | 0.190 |
Why?
|
| Inflammation | 3 | 2022 | 10638 | 0.190 |
Why?
|
| Sex Characteristics | 3 | 2021 | 2585 | 0.190 |
Why?
|
| Biopsy | 6 | 2018 | 6756 | 0.190 |
Why?
|
| Integrins | 3 | 2012 | 846 | 0.190 |
Why?
|
| Dermatitis | 1 | 2022 | 197 | 0.190 |
Why?
|
| Portugal | 1 | 2020 | 87 | 0.190 |
Why?
|
| Salts | 1 | 2020 | 65 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 5535 | 0.180 |
Why?
|
| Military Medicine | 1 | 2022 | 176 | 0.180 |
Why?
|
| Shock, Cardiogenic | 1 | 2005 | 688 | 0.180 |
Why?
|
| Pyrophosphatases | 2 | 2018 | 137 | 0.180 |
Why?
|
| Cetirizine | 1 | 2019 | 7 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 11725 | 0.170 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2018 | 197 | 0.170 |
Why?
|
| Tubulin | 1 | 2023 | 695 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2019 | 103 | 0.170 |
Why?
|
| Chloroquine | 1 | 2020 | 280 | 0.170 |
Why?
|
| Prostaglandin D2 | 1 | 2019 | 122 | 0.170 |
Why?
|
| Dinitrobenzenes | 2 | 2011 | 37 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13102 | 0.170 |
Why?
|
| Histamine H1 Antagonists | 1 | 2019 | 100 | 0.170 |
Why?
|
| Secretory Vesicles | 2 | 2012 | 124 | 0.160 |
Why?
|
| Cephalosporins | 1 | 2019 | 204 | 0.160 |
Why?
|
| Anesthesia, General | 3 | 2018 | 1171 | 0.160 |
Why?
|
| Quarantine | 1 | 2020 | 170 | 0.160 |
Why?
|
| Autopsy | 1 | 2022 | 1020 | 0.160 |
Why?
|
| Dermatofibrosarcoma | 1 | 2018 | 63 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 1041 | 0.160 |
Why?
|
| Mutation | 4 | 2022 | 29786 | 0.160 |
Why?
|
| Duodenum | 1 | 2021 | 483 | 0.160 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2014 | 652 | 0.160 |
Why?
|
| Hydroxyurea | 1 | 2019 | 290 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2017 | 4217 | 0.150 |
Why?
|
| Autonomic Nervous System | 1 | 2022 | 671 | 0.150 |
Why?
|
| Clinical Protocols | 4 | 2014 | 1462 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2019 | 1855 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 491 | 0.150 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 301 | 0.150 |
Why?
|
| Bradykinin | 1 | 2017 | 214 | 0.140 |
Why?
|
| Blood Coagulation | 2 | 2014 | 1127 | 0.140 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2018 | 188 | 0.140 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2017 | 39 | 0.140 |
Why?
|
| Cytokines | 3 | 2023 | 7322 | 0.140 |
Why?
|
| Outpatients | 2 | 2020 | 1486 | 0.140 |
Why?
|
| Young Adult | 13 | 2021 | 56430 | 0.140 |
Why?
|
| Flushing | 3 | 2011 | 49 | 0.140 |
Why?
|
| Societies | 1 | 2017 | 104 | 0.140 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 867 | 0.140 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 1782 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 57776 | 0.140 |
Why?
|
| Antibody Formation | 1 | 2021 | 1402 | 0.140 |
Why?
|
| Peptide Hydrolases | 3 | 1988 | 634 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 5181 | 0.140 |
Why?
|
| Stem Cell Factor | 1 | 1996 | 219 | 0.140 |
Why?
|
| Diphenhydramine | 2 | 2014 | 63 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 3798 | 0.140 |
Why?
|
| Diagnosis, Differential | 9 | 2021 | 12959 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 2 | 2006 | 199 | 0.130 |
Why?
|
| Risk | 2 | 2019 | 9687 | 0.130 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 297 | 0.130 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 712 | 0.130 |
Why?
|
| Risk Factors | 11 | 2020 | 72290 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2005 | 2924 | 0.130 |
Why?
|
| Immunoglobulins | 2 | 1999 | 881 | 0.130 |
Why?
|
| Bone Marrow Examination | 1 | 2015 | 157 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2023 | 2902 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2020 | 3209 | 0.120 |
Why?
|
| Receptors, IgG | 2 | 1997 | 582 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2022 | 1859 | 0.120 |
Why?
|
| Exercise | 2 | 2003 | 5615 | 0.120 |
Why?
|
| Melphalan | 1 | 2016 | 431 | 0.120 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2014 | 78 | 0.120 |
Why?
|
| Skin Diseases | 2 | 2021 | 1065 | 0.120 |
Why?
|
| Caspase 7 | 1 | 2013 | 56 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 2861 | 0.120 |
Why?
|
| Government Regulation | 1 | 2018 | 522 | 0.120 |
Why?
|
| Multigene Family | 2 | 1994 | 1102 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 639 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 1518 | 0.120 |
Why?
|
| Complement Activation | 1 | 2015 | 453 | 0.110 |
Why?
|
| Phenytoin | 1 | 2014 | 197 | 0.110 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2012 | 47 | 0.110 |
Why?
|
| Chymases | 4 | 2007 | 99 | 0.110 |
Why?
|
| Genes, Immunoglobulin | 1 | 1994 | 291 | 0.110 |
Why?
|
| Mice | 13 | 2023 | 81183 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 5 | 2011 | 6386 | 0.110 |
Why?
|
| Medicine | 1 | 2021 | 946 | 0.110 |
Why?
|
| Fibrin | 2 | 2014 | 506 | 0.110 |
Why?
|
| Thrombin | 2 | 2014 | 598 | 0.110 |
Why?
|
| Anesthesia, Obstetrical | 2 | 2013 | 235 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 459 | 0.110 |
Why?
|
| Sequence Deletion | 1 | 2017 | 1526 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1850 | 0.110 |
Why?
|
| Immune Tolerance | 2 | 2019 | 2258 | 0.110 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 537 | 0.100 |
Why?
|
| Time Factors | 5 | 2014 | 40075 | 0.100 |
Why?
|
| Fibrinogen | 2 | 2014 | 894 | 0.100 |
Why?
|
| Rifampin | 1 | 2014 | 315 | 0.100 |
Why?
|
| Child, Preschool | 6 | 2021 | 41006 | 0.100 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 280 | 0.100 |
Why?
|
| Prevalence | 3 | 2019 | 15226 | 0.100 |
Why?
|
| Adolescent | 12 | 2021 | 85781 | 0.100 |
Why?
|
| Estrogens | 1 | 2019 | 1566 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 1876 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 3923 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2018 | 1184 | 0.100 |
Why?
|
| gamma-Globulins | 1 | 2011 | 124 | 0.100 |
Why?
|
| Infant | 7 | 2019 | 35136 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 972 | 0.100 |
Why?
|
| Leukocytes | 2 | 2012 | 2043 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 1 | 2021 | 2731 | 0.100 |
Why?
|
| Shock | 1 | 2014 | 318 | 0.100 |
Why?
|
| Recurrence | 3 | 2020 | 8340 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 758 | 0.100 |
Why?
|
| Heart Rate | 1 | 2022 | 4091 | 0.100 |
Why?
|
| Nanoparticles | 2 | 2022 | 1905 | 0.100 |
Why?
|
| Latent Tuberculosis | 1 | 2014 | 225 | 0.100 |
Why?
|
| Fluid Therapy | 1 | 2015 | 593 | 0.100 |
Why?
|
| Fluorobenzenes | 1 | 2012 | 183 | 0.090 |
Why?
|
| Prednisone | 2 | 2018 | 1574 | 0.090 |
Why?
|
| Ranitidine | 1 | 2010 | 34 | 0.090 |
Why?
|
| Disease Progression | 4 | 2020 | 13284 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1584 | 0.090 |
Why?
|
| Propylene Glycol | 1 | 2010 | 32 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 1199 | 0.090 |
Why?
|
| Leukotrienes | 1 | 2012 | 255 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 35421 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2019 | 4445 | 0.090 |
Why?
|
| Excipients | 1 | 2010 | 96 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 2011 | 992 | 0.090 |
Why?
|
| Bone Marrow Cells | 4 | 2006 | 2513 | 0.090 |
Why?
|
| United States | 9 | 2022 | 69872 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 349 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3176 | 0.090 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2011 | 156 | 0.090 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2014 | 518 | 0.090 |
Why?
|
| Parabens | 1 | 2010 | 108 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6489 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2015 | 711 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2016 | 1598 | 0.080 |
Why?
|
| Health Personnel | 1 | 2022 | 3218 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2005 | 370 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 2274 | 0.080 |
Why?
|
| Immune System Diseases | 1 | 2011 | 262 | 0.080 |
Why?
|
| Immunization | 2 | 2021 | 1256 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2014 | 445 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1637 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2011 | 595 | 0.080 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2012 | 182 | 0.080 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 3036 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2021 | 778 | 0.080 |
Why?
|
| Venoms | 2 | 2018 | 91 | 0.070 |
Why?
|
| Family | 1 | 2018 | 3147 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2018 | 2531 | 0.070 |
Why?
|
| Cysteine | 1 | 2012 | 874 | 0.070 |
Why?
|
| Vomiting | 1 | 2010 | 636 | 0.070 |
Why?
|
| Liposomes | 2 | 2022 | 759 | 0.070 |
Why?
|
| Patients | 1 | 2013 | 900 | 0.070 |
Why?
|
| Algorithms | 2 | 2020 | 13881 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2018 | 2265 | 0.070 |
Why?
|
| Nasal Polyps | 1 | 2012 | 360 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2019 | 3309 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2022 | 8554 | 0.070 |
Why?
|
| Lipodystrophy | 1 | 2007 | 147 | 0.070 |
Why?
|
| Transfection | 2 | 2013 | 5892 | 0.070 |
Why?
|
| Serine Endopeptidases | 3 | 2006 | 1072 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 1998 | 2119 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 23338 | 0.070 |
Why?
|
| Emergency Service, Hospital | 3 | 2023 | 7659 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 693 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2661 | 0.070 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2006 | 98 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2021 | 6544 | 0.070 |
Why?
|
| Genome, Human | 1 | 2019 | 4420 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2015 | 2416 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2013 | 5179 | 0.070 |
Why?
|
| Picrates | 1 | 2005 | 13 | 0.070 |
Why?
|
| Nasal Mucosa | 1 | 1988 | 373 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 4933 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 10262 | 0.060 |
Why?
|
| Reference Standards | 1 | 2009 | 1025 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2021 | 1880 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 4851 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 3229 | 0.060 |
Why?
|
| Lung | 3 | 2022 | 9856 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 286 | 0.060 |
Why?
|
| Cell Line | 3 | 2019 | 15997 | 0.060 |
Why?
|
| Heparin | 1 | 2012 | 1637 | 0.060 |
Why?
|
| Perioperative Period | 2 | 2019 | 256 | 0.060 |
Why?
|
| Leiomyoma | 1 | 2010 | 730 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2006 | 527 | 0.060 |
Why?
|
| Stem Cells | 1 | 1997 | 3567 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2024 | 91 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2010 | 927 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2014 | 1916 | 0.060 |
Why?
|
| Insulin | 2 | 2009 | 6580 | 0.060 |
Why?
|
| Calcium | 2 | 2018 | 5756 | 0.060 |
Why?
|
| Peptides | 2 | 2014 | 4409 | 0.060 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2003 | 24 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2012 | 1938 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.050 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 841 | 0.050 |
Why?
|
| Research | 2 | 2021 | 1999 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15076 | 0.050 |
Why?
|
| Ukraine | 1 | 2022 | 111 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12245 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2014 | 3461 | 0.050 |
Why?
|
| Vitronectin | 1 | 2001 | 44 | 0.050 |
Why?
|
| Triazines | 1 | 2023 | 315 | 0.050 |
Why?
|
| Prognosis | 3 | 2014 | 29063 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2508 | 0.050 |
Why?
|
| Vegetables | 1 | 1986 | 1182 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2011 | 19229 | 0.050 |
Why?
|
| Acne Vulgaris | 1 | 2005 | 302 | 0.050 |
Why?
|
| Iron | 1 | 2009 | 1774 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2009 | 1401 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 2020 | 1547 | 0.050 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2012 | 2942 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2010 | 1513 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 1790 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2002 | 455 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 2795 | 0.050 |
Why?
|
| Diet | 1 | 2018 | 7939 | 0.050 |
Why?
|
| Florida | 1 | 2021 | 435 | 0.040 |
Why?
|
| Societies, Medical | 3 | 2018 | 3743 | 0.040 |
Why?
|
| Serum Sickness | 1 | 2019 | 28 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2006 | 2234 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2001 | 1157 | 0.040 |
Why?
|
| Pyrazolones | 1 | 2019 | 8 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 218 | 0.040 |
Why?
|
| Cesarean Section | 2 | 2021 | 1365 | 0.040 |
Why?
|
| Apoptosis | 2 | 2013 | 9727 | 0.040 |
Why?
|
| Sex Factors | 1 | 2013 | 10397 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2022 | 304 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5686 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 1095 | 0.040 |
Why?
|
| Pregnancy | 4 | 2021 | 29144 | 0.040 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 98 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 665 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5751 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 469 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 1988 | 0.040 |
Why?
|
| Bone Diseases | 1 | 2002 | 416 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2006 | 2263 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 8428 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2020 | 356 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3255 | 0.040 |
Why?
|
| Consensus Sequence | 2 | 1996 | 377 | 0.040 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 134 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2018 | 154 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 4149 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16689 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 3712 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 2541 | 0.040 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2006 | 1052 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 985 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 379 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 1146 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 93 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2915 | 0.030 |
Why?
|
| Emergency Medical Services | 2 | 2021 | 1917 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 1182 | 0.030 |
Why?
|
| Immunity | 1 | 2022 | 1012 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2017 | 496 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2015 | 62 | 0.030 |
Why?
|
| Vitamin D | 2 | 2020 | 3223 | 0.030 |
Why?
|
| Haptens | 1 | 2015 | 166 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2020 | 623 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2006 | 4026 | 0.030 |
Why?
|
| Signal Transduction | 4 | 2022 | 23403 | 0.030 |
Why?
|
| Dideoxynucleosides | 1 | 2015 | 122 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2004 | 1353 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 1999 | 2050 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 642 | 0.030 |
Why?
|
| Carbamazepine | 1 | 2015 | 229 | 0.030 |
Why?
|
| Connective Tissue Cells | 1 | 1994 | 55 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 950 | 0.030 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2018 | 417 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 9239 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 1223 | 0.030 |
Why?
|
| Comorbidity | 2 | 2020 | 10388 | 0.030 |
Why?
|
| Rifabutin | 1 | 2014 | 52 | 0.030 |
Why?
|
| Headache | 1 | 2002 | 1226 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2022 | 2740 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 25043 | 0.030 |
Why?
|
| Ligands | 1 | 2001 | 3282 | 0.030 |
Why?
|
| Brazil | 1 | 2018 | 1270 | 0.030 |
Why?
|
| Classification | 1 | 1994 | 129 | 0.030 |
Why?
|
| Inpatients | 1 | 2005 | 2518 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2014 | 89 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 114 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2017 | 696 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1996 | 2839 | 0.030 |
Why?
|
| Radiography | 2 | 2017 | 7023 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 9959 | 0.030 |
Why?
|
| Gene Expression | 3 | 2015 | 7799 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 310 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 738 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1997 | 1475 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 1085 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2023 | 1972 | 0.030 |
Why?
|
| Cost Savings | 1 | 2018 | 926 | 0.030 |
Why?
|
| Exons | 2 | 1999 | 2437 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 1785 | 0.030 |
Why?
|
| Myocardium | 1 | 2005 | 4776 | 0.030 |
Why?
|
| Incidence | 2 | 2018 | 20947 | 0.030 |
Why?
|
| Isoniazid | 1 | 2014 | 274 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 1147 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 390 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1992 | 318 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11524 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 591 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 627 | 0.030 |
Why?
|
| World Health Organization | 1 | 2017 | 1318 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 1997 | 1284 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2017 | 1061 | 0.030 |
Why?
|
| Iodine Compounds | 1 | 2011 | 30 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2002 | 1886 | 0.020 |
Why?
|
| Codeine | 1 | 2011 | 49 | 0.020 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2011 | 25 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2012 | 144 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6622 | 0.020 |
Why?
|
| Bronchoconstriction | 1 | 2012 | 143 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 551 | 0.020 |
Why?
|
| Egg Hypersensitivity | 1 | 2011 | 44 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2013 | 571 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2018 | 773 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1994 | 927 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2124 | 0.020 |
Why?
|
| India | 1 | 2017 | 2197 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 1581 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 1994 | 673 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2011 | 287 | 0.020 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2011 | 130 | 0.020 |
Why?
|
| Spleen | 1 | 1996 | 2362 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 2013 | 333 | 0.020 |
Why?
|
| Age of Onset | 1 | 2017 | 3271 | 0.020 |
Why?
|
| Acute Disease | 1 | 2021 | 7149 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 4776 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2022 | 1797 | 0.020 |
Why?
|
| Cell Count | 1 | 2014 | 1856 | 0.020 |
Why?
|
| Genes | 1 | 1994 | 1893 | 0.020 |
Why?
|
| Granulocytes | 1 | 2012 | 548 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1992 | 786 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2015 | 1381 | 0.020 |
Why?
|
| Dyspnea | 1 | 2017 | 1303 | 0.020 |
Why?
|
| Species Specificity | 1 | 1994 | 2478 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 1836 | 0.020 |
Why?
|
| Ribs | 1 | 2011 | 252 | 0.020 |
Why?
|
| DNA Primers | 1 | 1994 | 2892 | 0.020 |
Why?
|
| Learning | 1 | 2019 | 1713 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 13815 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2014 | 1726 | 0.020 |
Why?
|
| Nasal Provocation Tests | 1 | 1988 | 9 | 0.020 |
Why?
|
| Peanut Hypersensitivity | 1 | 2011 | 163 | 0.020 |
Why?
|
| Cell Division | 1 | 1996 | 4568 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2014 | 970 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1992 | 541 | 0.020 |
Why?
|
| Tacrolimus | 1 | 1992 | 743 | 0.020 |
Why?
|
| Protein Binding | 1 | 2001 | 9386 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2018 | 1580 | 0.020 |
Why?
|
| Antibodies | 1 | 2017 | 2460 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2003 | 4599 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2017 | 880 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
| Public Health | 1 | 2021 | 2603 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 4320 | 0.020 |
Why?
|
| Fishes | 1 | 2011 | 569 | 0.020 |
Why?
|
| Seafood | 1 | 2011 | 384 | 0.020 |
Why?
|
| Meat | 1 | 2011 | 592 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 571 | 0.020 |
Why?
|
| Anesthetics, Intravenous | 1 | 2011 | 417 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Edema | 1 | 2012 | 789 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 2703 | 0.020 |
Why?
|
| Radioallergosorbent Test | 1 | 1986 | 15 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2000 | 2303 | 0.020 |
Why?
|
| Base Sequence | 2 | 1999 | 12797 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 21827 | 0.020 |
Why?
|
| Pollen | 1 | 1986 | 75 | 0.020 |
Why?
|
| Anesthesia, Spinal | 1 | 2010 | 269 | 0.020 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1986 | 131 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1987 | 252 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1996 | 3748 | 0.020 |
Why?
|
| Health Behavior | 1 | 2018 | 2636 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3158 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 608 | 0.020 |
Why?
|
| Spain | 1 | 2007 | 465 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2014 | 1367 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 2540 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1987 | 719 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1994 | 4011 | 0.020 |
Why?
|
| Alleles | 1 | 2017 | 6933 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2018 | 3444 | 0.020 |
Why?
|
| Bone Density | 1 | 2018 | 3468 | 0.020 |
Why?
|
| Analgesia | 1 | 2010 | 461 | 0.020 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 1996 | 53 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1996 | 3474 | 0.020 |
Why?
|
| Propofol | 1 | 2011 | 629 | 0.020 |
Why?
|
| Hypotension | 1 | 2011 | 884 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 18111 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2011 | 1063 | 0.020 |
Why?
|
| Plant Proteins | 1 | 1986 | 364 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 6171 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1986 | 1801 | 0.010 |
Why?
|
| Analgesics | 1 | 2011 | 1040 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 3479 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3870 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1987 | 772 | 0.010 |
Why?
|
| Health Surveys | 1 | 2013 | 4037 | 0.010 |
Why?
|
| Immunoassay | 1 | 1987 | 752 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 2576 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 4251 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2011 | 2052 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18029 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 2728 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2018 | 4558 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2011 | 10180 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3064 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2021 | 25625 | 0.010 |
Why?
|
| Epitopes | 1 | 2008 | 2571 | 0.010 |
Why?
|
| Physicians | 1 | 2019 | 4567 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 11366 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 5524 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 19905 | 0.010 |
Why?
|
| DNA | 1 | 1994 | 7301 | 0.010 |
Why?
|
| Rhinitis | 1 | 2007 | 691 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1996 | 11483 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2014 | 9146 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 3068 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1992 | 5021 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3086 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.010 |
Why?
|
| Echocardiography | 1 | 2011 | 5102 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.010 |
Why?
|
| Sinusitis | 1 | 2007 | 923 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15519 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2011 | 6442 | 0.010 |
Why?
|
| Receptor Aggregation | 1 | 1996 | 80 | 0.010 |
Why?
|
| Introns | 1 | 1999 | 991 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 14557 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2014 | 21746 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 1202 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 15165 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 12072 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 2872 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 4215 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 3336 | 0.010 |
Why?
|
| Amino Acid Isomerases | 1 | 1992 | 34 | 0.010 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 1992 | 105 | 0.010 |
Why?
|
| Tyrosine | 1 | 1996 | 1461 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1996 | 2256 | 0.010 |
Why?
|
| Calcineurin | 1 | 1992 | 226 | 0.010 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 1992 | 195 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 7913 | 0.010 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1992 | 249 | 0.010 |
Why?
|
| Exocytosis | 1 | 1992 | 353 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1992 | 337 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 20129 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 3494 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1999 | 5974 | 0.010 |
Why?
|
| Penis | 1 | 1987 | 216 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2008 | 40561 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1987 | 791 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1987 | 1801 | 0.000 |
Why?
|